Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rallybio ( (RLYB) ) has provided an announcement.
On January 26, 2026, Rallybio Corporation’s stockholders approved an amendment to its Certificate of Incorporation authorizing a reverse stock split of its common stock at a ratio selected by the board, and the company subsequently fixed the split at 1-for-8. The reverse stock split, scheduled to take effect at 12:01 a.m. Eastern Time on February 6, 2026, will consolidate Rallybio’s issued and outstanding shares and result in its common stock trading on a post-split basis under a new CUSIP, a move that typically aims to boost the per-share trading price and can influence the company’s market perception and compliance with stock exchange listing requirements; the vote passed with a strong majority, with more than 34.5 million shares in favor out of approximately 35 million shares voted, indicating broad shareholder support for the capital structure change.
The most recent analyst rating on (RLYB) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Rallybio stock, see the RLYB Stock Forecast page.
Spark’s Take on RLYB Stock
According to Spark, TipRanks’ AI Analyst, RLYB is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, sizable losses, and ongoing cash burn despite low debt). Technicals are mixed-to-stable with modest positive momentum and an improving longer-term moving-average structure. Valuation is difficult to assess favorably due to negative earnings and no dividend yield data.
To see Spark’s full report on RLYB stock, click here.
More about Rallybio
Rallybio Corporation is a biopharmaceutical company whose common stock is listed and actively traded on a public exchange, with a shareholder base of over 42 million shares outstanding as of December 30, 2025, reflecting its positioning as a publicly held player in the healthcare sector.
Average Trading Volume: 198,685
Technical Sentiment Signal: Sell
Current Market Cap: $27.04M
For a thorough assessment of RLYB stock, go to TipRanks’ Stock Analysis page.